PURPOSE: Concurrent cisplatin-based chemoradiotherapy (CRT) is the standard treatment
for locally advanced cervical cancer. RTOG 0417 was a Phase II study exploring the safety …

Introduction: Bevacizumab is a recombinant humanized monoclonal antibody against
vascular endothelial growth factor (VEGF).(Avastin; Genetech, Inc, San Francisco, CA) …

Introduction Cervical cancer is the fourth common cancer in women worldwide. While, in the
past, locally advanced stage disease was treated by pelvic radiotherapy, nowadays the …

The prognosis of patients with metastatic cervical cancer is poor with a median survival of 8–
13 months. Despite the potency of chemotherapeutic drugs, this treatment is rarely curative …

Cervical cancer is a public health issue in developing countries. Although the Pap smear
and colposcopy remain the major strategies for detection, most cases are diagnosed in the …

The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for
treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical …

Management of locally advanced cervix cancer underwent major change 2 decades back
when concurrent chemotherapy (CCRT)(with cisplatin alone or in combination) along with …

OBJECTIVE: To review the clinical trial experience with chemotherapy for patients with
primary Stage IVB, persistent and recurrent cervical cancer. METHODS: PubMed and …

OBJECTIVE: cisplatin (Cp) plus topotecan (Tc) is the first combination chemotherapy to
demonstrate a survival advantage over cisplatin alone in advanced cervical cancer …

Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240,
the incorporation of bevacizumab with chemotherapy significantly increased overall survival …